Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talabostat and Gemcitabine in Stage IV Pancreatic Cancer
NCT00116389Phase 2Terminated
- Sponsor
- Point Therapeutics
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talabostat in pancreatic ductal adenocarcinoma (PDAC), sponsored by Point Therapeutics. Status: terminated.
02
Drugs
talabostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00116389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116389.